Display options
Cite
Ambady P, Wu YJ, Kersch CN, et al. Radiation enhances the delivery of antisense oligonucleotides and improves chemo-radiation efficacy in brain tumor xenografts. Cancer Gene Ther. 2021;doi: 10.1038/s41417-021-00324-6.
Ambady, P., Wu, Y. J., Kersch, C. N., Walker, J. M., Holland, S., Muldoon, L. L., & Neuwelt, E. A. (2021). Radiation enhances the delivery of antisense oligonucleotides and improves chemo-radiation efficacy in brain tumor xenografts. Cancer gene therapy, . https://doi.org/10.1038/s41417-021-00324-6
Ambady, Prakash, et al. "Radiation enhances the delivery of antisense oligonucleotides and improves chemo-radiation efficacy in brain tumor xenografts." Cancer gene therapy vol. (2021). doi: https://doi.org/10.1038/s41417-021-00324-6
Ambady P, Wu YJ, Kersch CN, Walker JM, Holland S, Muldoon LL, Neuwelt EA. Radiation enhances the delivery of antisense oligonucleotides and improves chemo-radiation efficacy in brain tumor xenografts. Cancer Gene Ther. 2021 Apr 14; doi: 10.1038/s41417-021-00324-6. Epub 2021 Apr 14. PMID: 33850305.
Copy Download .nbib Format: NLM
Share it on

Cancer Gene Ther. 2021 Apr 14; doi: 10.1038/s41417-021-00324-6. Epub 2021 Apr 14.

Radiation enhances the delivery of antisense oligonucleotides and improves chemo-radiation efficacy in brain tumor xenografts.

Cancer gene therapy

Prakash Ambady, Yingjen Jeffrey Wu, Cymon N Kersch, Joshua M Walker, Samantha Holland, Leslie L Muldoon, Edward A Neuwelt

Affiliations

  1. Department of Neurology, Oregon Health and Sciences University, Portland, OR, USA. [email protected].
  2. Department of Neurology, Oregon Health and Sciences University, Portland, OR, USA.
  3. Department of Cell, Developmental and Cancer Biology, Oregon Health and Science University, Portland, OR, USA.
  4. Department of Radiation Medicine, Oregon Health and Science University, Portland, OR, USA.
  5. Department of Neurosurgery, Oregon Health and Science University, Portland, OR, USA.
  6. Department of Veterans Affairs Medical Center, Office of Research and Development, Portland, OR, USA.

PMID: 33850305 DOI: 10.1038/s41417-021-00324-6

Abstract

Overexpression of O

References

  1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96. - PubMed
  2. Yu W, Zhang L, Wei Q, Shao A. O(6)-methylguanine-DNA methyltransferase (MGMT): challenges and new opportunities in glioma chemotherapy. Front Oncol. 2019;9:1547. - PubMed
  3. Bobola MS, Berger MS, Silber JR. Contribution of O6-methylguanine-DNA methyltransferase to resistance to 1,3-(2-chloroethyl)-1-nitrosourea in human brain tumor-derived cell lines. Mol Carcinog. 1995;13:81–8. - PubMed
  4. Carlson BL, Grogan PT, Mladek AC, Schroeder MA, Kitange GJ, Decker PA, et al. Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts. Int J Radiat Oncol Biol Phys. 2009;75:212–9. - PubMed
  5. Jiang G, Jiang AJ, Xin Y, Li LT, Cheng Q, Zheng JN. Progression of O(6)-methylguanine-DNA methyltransferase and temozolomide resistance in cancer research. Mol Biol Rep. 2014;41:6659–65. - PubMed
  6. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997–1003. - PubMed
  7. Stirchak EP, Summerton JE, Weller DD. Uncharged stereoregular nucleic acid analogs: 2. Morpholino nucleoside oligomers with carbamate internucleoside linkages. Nucleic Acids Res. 1989;17:6129–41. - PubMed
  8. Summerton J, Weller D. Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev. 1997;7:187–95. - PubMed
  9. MacLeod AR, Crooke ST. RNA therapeutics in oncology: advances, challenges, and future directions. J Clin Pharmacol. 2017;57(Suppl 10):S43–S59. - PubMed
  10. Ambady P, Wu YJ, Walker JM, Kersch C, Pagel MA, Woltjer RL, et al. Enhancing the cytotoxicity of chemoradiation with radiation-guided delivery of anti-MGMT morpholino oligonucleotides in non-methylated solid tumors. Cancer Gene Ther. 2017;24:348–57. - PubMed
  11. Puhalla S, Elmquist W, Freyer D, Kleinberg L, Adkins C, Lockman P, et al. Unsanctifying the sanctuary: challenges and opportunities with brain metastases. Neuro Oncol. 2015;17:639–51. - PubMed
  12. Aartsma-Rus A, Krieg AM. FDA approves eteplirsen for duchenne muscular dystrophy: the next chapter in the eteplirsen saga. Nucleic Acid Ther. 2017;27:1–3. - PubMed
  13. Scoles DR, Pulst SM. Oligonucleotide therapeutics in neurodegenerative diseases. RNA Biol. 2018;15:707–14. - PubMed
  14. Trnovec T, Kallay Z, Bezek S. Effects of ionizing radiation on the blood brain barrier permeability to pharmacologically active substances. Int J Radiat Oncol Biol Phys. 1990;19:1581–7. - PubMed
  15. Fauquette W, Amourette C, Dehouck MP, Diserbo M. Radiation-induced blood-brain barrier damages: an in vitro study. Brain Res. 2012;1433:114–26. - PubMed
  16. Diserbo M, Agin A, Lamproglou I, Mauris J, Staali F, Multon E, et al. Blood-brain barrier permeability after gamma whole-body irradiation: an in vivo microdialysis study. Can J Physiol Pharm. 2002;80:670–8. - PubMed
  17. Nakata H, Yoshimine T, Murasawa A, Kumura E, Harada K, Ushio Y, et al. Early blood-brain barrier disruption after high-dose single-fraction irradiation in rats. Acta Neurochir. 1995;136:82–6. ; discussion 6-7 - PubMed
  18. Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Rich JN, et al. Phase I trial of temozolomide plus O - PubMed
  19. Broniscer A, Gururangan S, MacDonald TJ, Goldman S, Packer RJ, Stewart CF, et al. Phase I trial of single-dose temozolomide and continuous administration of O - PubMed
  20. Weingart J, Grossman SA, Carson KA, Fisher JD, Delaney SM, Rosenblum ML, et al. Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O - PubMed
  21. Wu YJ, Neuwelt AJ, Muldoon LL, Neuwelt EA. Acetaminophen enhances cisplatin- and paclitaxel-mediated cytotoxicity to SKOV3 human ovarian carcinoma. Anticancer Res. 2013;33:2391–400. - PubMed
  22. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9:671–5. - PubMed
  23. Wang L, Prakash RK, Stein CA, Koehn RK, Ruffner DE. Progress in the delivery of therapeutic oligonucleotides: organ/cellular distribution and targeted delivery of oligonucleotides in vivo. Antisense Nucleic Acid Drug Dev. 2003;13:169–89. - PubMed
  24. Asami Y, Yoshioka K, Nishina K, Nagata T, Yokota T. Drug delivery system of therapeutic oligonucleotides. Drug Disco Ther. 2016;10:256–62. - PubMed
  25. Juliano RL. The delivery of therapeutic oligonucleotides. Nucleic Acids Res. 2016;44:6518–48. - PubMed
  26. Naidoo J, Panday H, Jackson S, Grossman SA. Optimizing the delivery of antineoplastic therapies to the central nervous system. Oncology. 2016;30:953–62. - PubMed
  27. Neuwelt E, Ambady P, Muldoon L, McConnell H, Doolittle N. Outwitting the blood-brain barrier. Oncology. 2016;30:963 - PubMed
  28. Morcos PA, Li Y, Jiang S. Vivo-Morpholinos: a non-peptide transporter delivers Morpholinos into a wide array of mouse tissues. Biotechniques. 2008;45:613–4. 6,passim - PubMed
  29. Pardridge WM. Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab. 2012;32:1959–72. - PubMed
  30. Lockman PR, Mittapalli RK, Taskar KS, Rudraraju V, Gril B, Bohn KA, et al. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res. 2010;16:5664–78. - PubMed
  31. Oh IS, Shimizu H, Satoh T, Okada S, Adachi S, Inoue K, et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature. 2006;443:709–12. - PubMed
  32. Silvestre DC, Gil GA, Tomasini N, Bussolino DF, Caputto BL. Growth of peripheral and central nervous system tumors is supported by cytoplasmic c-Fos in humans and mice. PLoS ONE. 2010;5:e9544. - PubMed
  33. Oh IS, Shimizu H, Sato T, Uehara Y, Okada S, Mori M. Molecular mechanisms associated with leptin resistance: n-3 polyunsaturated fatty acids induce alterations in the tight junction of the brain. Cell Metab. 2005;1:331–41. - PubMed
  34. Pardridge WM. Drug transport in brain via the cerebrospinal fluid. Fluids Barriers CNS. 2011;8:7. - PubMed
  35. Mak M, Fung L, Strasser JF, Saltzman WM. Distribution of drugs following controlled delivery to the brain interstitium. J Neurooncol. 1995;26:91–102. - PubMed
  36. Blasberg RG, Patlak C, Fenstermacher JD. Intrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion. J Pharm Exp Ther. 1975;195:73–83. - PubMed
  37. Qin DX, Zheng R, Tang J, Li JX, Hu YH. Influence of radiation on the blood-brain barrier and optimum time of chemotherapy. Int J Radiat Oncol Biol Phys. 1990;19:1507–10. - PubMed
  38. Cao Y, Tsien CI, Shen Z, Tatro DS, Ten Haken R, Kessler ML, et al. Use of magnetic resonance imaging to assess blood-brain/blood-glioma barrier opening during conformal radiotherapy. J Clin Oncol. 2005;23:4127–36. - PubMed
  39. Fan CH, Liu WL, Cao H, Wen C, Chen L, Jiang G. O - PubMed
  40. Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Rich JN, et al. Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol. 2009;27:1262–7. - PubMed
  41. Watson AJ, Sabharwal A, Thorncroft M, McGown G, Kerr R, Bojanic S, et al. Tumor O(6)-methylguanine-DNA methyltransferase inactivation by oral lomeguatrib. Clin Cancer Res. 2010;16:743–9. - PubMed
  42. Rood BR, Zhang H, Cogen PH. Intercellular heterogeneity of expression of the MGMT DNA repair gene in pediatric medulloblastoma. Neuro Oncol. 2004;6:200–7. - PubMed
  43. Ranson M, Middleton MR, Bridgewater J, Lee SM, Dawson M, Jowle D, et al. Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res. 2006;12:1577–84. - PubMed

Publication Types

Grant support